inshorts

Vaccine for blood cancer passes key trial

A vaccine named galinpepimut-S (GPS) for acute myeloid leukemia (AML) passed the Phase 3 REGAL trial, drugmaker Sellas Life Sciences announced. The vaccine was tested on 126 patients with AML, an aggressive type of blood cancer. The median survival of those who got the vaccine reached 24 months, compared to 14.7 months in the control group, the company claimed.